Clinical trials of Bharat Biotech’s intranasal COVID vaccine candidate as a primary (two) dose and a heterologous booster dose have been completed and the data submitted for approval to national regulatory authorities.
BBV154, the vaccine, has proven to be safe, well-tolerated and immunogenic in controlled clinical trials, the vaccine maker said announcing submission of the data on completion of the trials in which nearly 4,000 volunteers participated.
“On this 75th Independence Day, we are proud to announce successful completion of clinical trials for BBV154 intranasal vaccine. If approved, this vaccine will make it easier to deploy in mass immunization campaigns with an easy to administer formulation and delivery device,” Joint Managing Director Suchitra K. Ella said.
